Tower Research Capital LLC TRC Has $31,000 Position in Qiagen (NYSE:QGEN)

Tower Research Capital LLC TRC lifted its holdings in shares of Qiagen (NYSE:QGEN) by 66.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 710 shares of the company’s stock after buying an additional 283 shares during the period. Tower Research Capital LLC TRC’s holdings in Qiagen were worth $31,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Lindbrook Capital LLC boosted its position in Qiagen by 21.6% during the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after purchasing an additional 237 shares during the period. Xponance Inc. grew its stake in Qiagen by 2.7% in the 4th quarter. Xponance Inc. now owns 9,609 shares of the company’s stock valued at $417,000 after buying an additional 253 shares during the last quarter. Signaturefd LLC raised its holdings in Qiagen by 9.0% in the 3rd quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock valued at $190,000 after acquiring an additional 385 shares during the period. Eagle Asset Management Inc. lifted its position in Qiagen by 2.2% during the fourth quarter. Eagle Asset Management Inc. now owns 20,338 shares of the company’s stock worth $883,000 after acquiring an additional 430 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in Qiagen by 2.6% during the fourth quarter. Sequoia Financial Advisors LLC now owns 18,499 shares of the company’s stock worth $803,000 after buying an additional 461 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Trading Up 0.7 %

QGEN traded up $0.30 during trading on Friday, reaching $42.98. 1,317,948 shares of the stock traded hands, compared to its average volume of 1,175,720. The company has a quick ratio of 1.62, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. The stock’s 50-day moving average is $42.53 and its 200 day moving average is $42.73. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.70. The stock has a market capitalization of $9.81 billion, a PE ratio of 28.85, a P/E/G ratio of 3.61 and a beta of 0.42.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The firm’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.53 EPS. Equities analysts anticipate that Qiagen will post 2.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

QGEN has been the subject of several analyst reports. Stifel Nicolaus dropped their price objective on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a report on Wednesday. Citigroup cut their price objective on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Morgan Stanley upgraded shares of Qiagen from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $49.48 to $51.00 in a research report on Friday, February 16th. Finally, JPMorgan Chase & Co. increased their price target on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.95.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.